Watchlist Price Alert

Heron Therapeutics Inc. (HRTX)

NASDAQ: HRTX · Real-Time Price · USD

2.10

0.10 (5.00%)

At close: Jun 06, 2025, 3:59 PM

2.07

-1.19%

After-hours: Jun 06, 2025, 05:39 PM EDT

5.00% (1D)

Bid	2.07
Market Cap	319.62M
Revenue (ttm)	157.98M
Net Income (ttm)	-7.79M
EPS (ttm)	-0.05
PE Ratio (ttm)	-41.9
Forward PE	25.62
Analyst	Buy

Ask	2.1
Volume	1,630,596
Avg. Volume (20D)	1,532,868
Open	2.06
Previous Close	2.00
Day's Range	2.06 - 2.15
52-Week Range	1.04 - 3.93
Beta	1.17

About HRTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HRTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+13.62%

Heron Therapeutics shares are trading higher after... Unlock content with Pro Subscription

3 months ago

+20.49%

Heron Therapeutics shares are trading higher following better-than-expected Q4 financial results.

News

1 month ago · seekingalpha.com

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-yea...

1 month ago · seekingalpha.com

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer I...

1 month ago · zacks.com

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metric...

1 month ago · zacks.com

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.

1 month ago · zacks.com

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.